Last10K.com

Aravive, Inc. (ARAV) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Aravive, Inc.

CIK: 1513818 Ticker: ARAV
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 25, 2022
Jun. 30, 2021
Document Information [Line Items]   
Entity Central Index Key0001513818  
Entity Registrant NameAravive, Inc.  
Amendment Flagfalse  
Current Fiscal Year End Date--12-31  
Document Fiscal Period FocusFY  
Document Fiscal Year Focus2021  
Document Type10-K  
Document Annual Reporttrue  
Document Period End DateDec. 31, 2021  
Document Transition Reportfalse  
Entity File Number001-36361  
Entity Incorporation, State or Country CodeDE  
Entity Tax Identification Number26-4106690  
Entity Address, Address Line One3730 Kirby Drive, Suite 1200  
Entity Address, City or TownHouston  
Entity Address, State or ProvinceTX  
Entity Address, Postal Zip Code77098  
City Area Code936  
Local Phone Number355-1910  
Title of 12(b) SecurityCommon stock, par value $0.0001 per share  
Trading SymbolARAV  
Security Exchange NameNASDAQ  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Current Reporting StatusYes  
Entity Interactive Data CurrentYes  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companyfalse  
ICFR Auditor Attestation Flagfalse  
Entity Shell Companyfalse  
Entity Public Float  $ 89,127,600
Entity Common Stock, Shares Outstanding 21,094,357 
Auditor NameBDO USA, LLP  
Auditor LocationRaleigh, NC  
Auditor Firm ID243  

View differences made from one year to another to evaluate Aravive, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aravive, Inc..

Continue

Assess how Aravive, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aravive, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Revenue
Other
Filter by Subcategory:
All
Expense
Shares
Geography
Product
Income
Other
Inside Aravive, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parentheticals)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Cash Flows (Parentheticals)
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders&Amp;#8217; Equity
Consolidated Statements Of Stockholders&Amp;#8217; Equity (Parentheticals)
Note 1 - Formation And Business Of The Company
Note 1 - Formation And Business Of The Company (Details Textual)
Note 10 - Income Taxes
Note 10 - Income Taxes (Details Textual)
Note 10 - Income Taxes (Tables)
Note 10 - Income Taxes - Effect Income Tax Rate Reconciliation (Details)
Note 10 - Income Taxes - Net Deferred Tax Assets (Details)
Note 10 - Income Taxes - Provision (Benefit) For Federal Income Taxes (Details)
Note 10 - Income Taxes - Unrecognized Tax Benefits (Details)
Note 11 - Employee Benefit Plans
Note 11 - Employee Benefit Plans (Details Textual)
Note 12 - Net Loss Per Share Of Common Stock
Note 12 - Net Loss Per Share Of Common Stock (Details Textual)
Note 12 - Net Loss Per Share Of Common Stock (Tables)
Note 12 - Net Loss Per Share Of Common Stock - Antidilutive Securities (Details)
Note 12 - Net Loss Per Share Of Common Stock - Summary Of Computation Of Basic And Diluted Net Loss Per Share (Details)
Note 13 - Subsequent Events
Note 13 - Subsequent Events (Details Textual)
Note 2 - Summary Of Significant Accounting Policies
Note 2 - Summary Of Significant Accounting Policies (Details Textual)
Note 3 - Balance Sheet Components
Note 3 - Balance Sheet Components (Details Textual)
Note 3 - Balance Sheet Components (Tables)
Note 3 - Balance Sheet Components - Schedule Of Accrued Liabilities (Details)
Note 3 - Balance Sheet Components - Schedule Of Balance Sheet Components (Details)
Note 3 - Balance Sheet Components - Schedule Of Property And Equipment, Net (Details)
Note 4 - Fair Value Measurements
Note 4 - Fair Value Measurements (Details Textual)
Note 4 - Fair Value Measurements (Tables)
Note 4 - Fair Value Measurements - Financial Instruments Measured At Fair Value On A Recurring Basis (Details)
Note 5 - Collaboration And License Agreement
Note 5 - Collaboration And License Agreement 1 (Details Textual)
Note 5 - Collaboration And License Agreement 2 (Details Textual)
Note 6 - Leases
Note 6 - Leases (Details Textual)
Note 6 - Leases (Tables)
Note 6 - Leases - Future Based Rent (Details)
Note 6 - Leases - Minimum Lease Payments Under Non-Cancellable Operating Leases (Details)
Note 7 - Commitments And Contingencies
Note 7 - Commitments And Contingencies (Details Textual)
Note 8 - Common Stock
Note 8 - Common Stock (Details Textual)
Note 8 - Common Stock (Tables)
Note 8 - Common Stock - Reserved Shares Of Common Stock For Future Issuances (Details)
Note 9 - Stock Based Awards
Note 9 - Stock Based Awards (Details Textual)
Note 9 - Stock Based Awards (Tables)
Note 9 - Stock Based Awards - Activity Under Stock Option Plan (Details)
Note 9 - Stock Based Awards - Stock-Based Compensation Expense (Details)
Note 9 - Stock Based Awards - Weighted-Average Assumptions (Details)
Significant Accounting Policies (Policies)
Ticker: ARAV
CIK: 1513818
Form Type: 10-K Annual Report
Accession Number: 0001437749-22-007827
Submitted to the SEC: Thu Mar 31 2022 3:00:48 PM EST
Accepted by the SEC: Thu Mar 31 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/arav/0001437749-22-007827.htm